MURDOCH CHILDRENS RESEARCH INSTITUTE PUBLIC COMPANY LBG

Their core work

Murdoch Children's Research Institute (MCRI) is one of Australia's leading paediatric research centres, based in Melbourne. They specialize in child and adolescent health, rare genetic disorders, and developmental toxicology. In H2020, they contributed clinical expertise on skeletal dysplasia drug repurposing, child health service delivery models, and endocrine disruptor testing — bringing Southern Hemisphere clinical cohorts and specialized paediatric knowledge to European consortia.

What they specialise in

How they've shifted over time

MCRI's early H2020 involvement (2015-2016) centred on population-level child health — primary care delivery, school health systems, and health economics. From 2017 onward, they shifted decisively toward molecular and clinical research: rare disease drug repurposing, endocrine disruptor testing with advanced in vitro and in silico tools, and biomarker development. This reflects a move from health services research toward translational medicine and regulatory science.

MCRI is moving toward translational paediatric research — drug repurposing, biomarker discovery, and regulatory toxicology — making them increasingly relevant for clinical trial and rare disease consortia.

How they like to work

MCRI never coordinated an H2020 project, consistently joining as participant or third party — reflecting their role as a non-European specialist contributor brought in for specific expertise. With 54 unique partners across 20 countries from just 4 projects, they operate in large, diverse consortia rather than tight bilateral arrangements. This suggests they are valued for niche capabilities (paediatric cohorts, rare disease clinical data) that European consortia cannot easily source locally.

Despite only 4 projects, MCRI has built connections with 54 partners across 20 countries — an unusually wide network driven by participation in large multinational health consortia. Their reach is truly global, bridging Australian clinical expertise with European research infrastructure.

What sets them apart

As an Australian paediatric research institute, MCRI offers something most European partners cannot: access to Southern Hemisphere clinical populations, Australian regulatory perspectives, and deep paediatric specialization. Their dual strength in rare genetic disorders (skeletal dysplasia) and environmental health (endocrine disruptors in children) is an unusual combination. For consortium builders, MCRI adds both geographic diversity and clinical credibility in child-specific research areas.

Highlights from their portfolio

• MCDS-Therapy
  Their only directly funded project (EUR 340,625), targeting drug repurposing for a rare skeletal disorder — a concrete translational medicine effort with clinical trial ambitions.
• ENDpoiNTs
  Large-scale project (2019-2024) developing next-generation testing for endocrine disruptors affecting child brain development, combining in vitro, in silico, omics, and epidemiological methods.
• MOCHA
  Multinational evaluation of child health care models across Europe, positioning MCRI as a comparator for non-European health system benchmarking.